BRPI0908706A2 - Inibidores de mólecula pequena solúvel em água do regulador de condutância de transmembrana de fibrose cística - Google Patents
Inibidores de mólecula pequena solúvel em água do regulador de condutância de transmembrana de fibrose císticaInfo
- Publication number
- BRPI0908706A2 BRPI0908706A2 BRPI0908706-0A BRPI0908706A BRPI0908706A2 BR PI0908706 A2 BRPI0908706 A2 BR PI0908706A2 BR PI0908706 A BRPI0908706 A BR PI0908706A BR PI0908706 A2 BRPI0908706 A2 BR PI0908706A2
- Authority
- BR
- Brazil
- Prior art keywords
- water soluble
- small molecule
- cystic fibrosis
- molecule inhibitors
- fibrosis transmembrane
- Prior art date
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3937908P | 2008-03-25 | 2008-03-25 | |
| US8422808P | 2008-07-28 | 2008-07-28 | |
| PCT/US2009/038292 WO2009120803A2 (en) | 2008-03-25 | 2009-03-25 | Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0908706A2 true BRPI0908706A2 (pt) | 2015-07-28 |
Family
ID=40846988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908706-0A BRPI0908706A2 (pt) | 2008-03-25 | 2009-03-25 | Inibidores de mólecula pequena solúvel em água do regulador de condutância de transmembrana de fibrose cística |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110105565A1 (pt) |
| EP (1) | EP2279029A2 (pt) |
| JP (1) | JP2011517674A (pt) |
| KR (1) | KR20100134063A (pt) |
| AU (1) | AU2009228307A1 (pt) |
| BR (1) | BRPI0908706A2 (pt) |
| CA (1) | CA2718436A1 (pt) |
| MX (1) | MX2010010343A (pt) |
| WO (1) | WO2009120803A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509282A (pt) | 2004-03-30 | 2007-09-18 | Univ California | compostos contendo hidrazida inibidores de cftr e seus usos |
| EP2117601A2 (en) | 2006-12-22 | 2009-11-18 | The Regents of the University of California | Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| EP2464354B1 (en) | 2009-08-10 | 2015-04-01 | The Regents of The University of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| USRE48842E1 (en) | 2011-05-27 | 2021-12-07 | The Regents Of The University Of California | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| FR2999191B1 (fr) * | 2012-12-12 | 2016-02-05 | Lesaffre & Cie | Souches probiotiques pour le traitement et/ou la prevention de la diarrhee |
| CN104557764B (zh) * | 2015-02-15 | 2017-06-16 | 山东大学 | 3,5‑二取代绕丹宁类抗凋亡蛋白Bcl‑2抑制剂及制备方法和应用 |
| WO2016196297A1 (en) | 2015-05-29 | 2016-12-08 | Emory University | 2-amino-n'-benzylideneacetohydrazides and derivatives for the management of cftr protein mediated diseases |
| WO2016196303A1 (en) | 2015-05-29 | 2016-12-08 | Emory University | 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases |
| CN109111408B (zh) * | 2017-06-26 | 2021-03-09 | 中国科学技术大学 | 噻唑啉酮杂环化合物、其制备方法、药用组合物及应用 |
| US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| CN114007623A (zh) | 2019-06-12 | 2022-02-01 | 加利福尼亚大学董事会 | 治疗胆汁酸性腹泻的方法 |
| WO2025121320A1 (ja) * | 2023-12-04 | 2025-06-12 | 国立大学法人山口大学 | 多発性嚢胞腎の予防又は治療剤 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US393507A (en) * | 1888-11-27 | Account-book | ||
| US3280136A (en) * | 1965-05-03 | 1966-10-18 | Gen Electric | 5-substituted-2, 4-oxazolidinediones and magnesium chelate intermediates therefor |
| JPS505260B1 (pt) * | 1970-09-04 | 1975-03-01 | ||
| BE787340A (nl) * | 1971-08-12 | 1973-02-09 | Agfa Gevaert Nv | Lichtgevoelig, thermisch ontwikkelbaar materiaal op basis van spectraalgesensibiliseerde organische zilverzouten |
| US4859228A (en) * | 1987-07-16 | 1989-08-22 | Ici Americas Inc | Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones |
| DE3837576A1 (de) * | 1988-11-05 | 1990-05-10 | Bayer Ag | 5-carbamoyl-thiazolidine, verfahren zu ihrer herstellung und ihre verwendung als parasitizide |
| US5326770A (en) * | 1992-07-17 | 1994-07-05 | The Du Pont Merck Pharmaceutical Company | Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals |
| UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| WO2003105840A2 (en) * | 2002-06-17 | 2003-12-24 | The Pennsylvania State Research Foundation | Sphingosine kinase inhibitors |
| US7232573B1 (en) * | 2002-09-26 | 2007-06-19 | Advanced Cardiovascular Systems, Inc. | Stent coatings containing self-assembled monolayers |
| US20040063695A1 (en) * | 2002-09-30 | 2004-04-01 | Alan Verkman | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| AU2003277162C1 (en) * | 2002-09-30 | 2009-12-24 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| US7235573B2 (en) * | 2002-09-30 | 2007-06-26 | The Regents Of The University Of California | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors |
| WO2004093803A2 (en) * | 2003-04-16 | 2004-11-04 | Pintex Pharmaceuticals, Inc. | Photochemotherapeutic compounds for use in treatment of pin1-associated states |
| EP1666469A4 (en) * | 2003-09-11 | 2008-12-03 | Inst Med Molecular Design Inc | INHIBITOR OF PLASMINOGENACTIVATORINHIBITOR-1 |
| BRPI0509282A (pt) * | 2004-03-30 | 2007-09-18 | Univ California | compostos contendo hidrazida inibidores de cftr e seus usos |
| JP2007063443A (ja) * | 2005-08-31 | 2007-03-15 | Tdk Corp | 錯化合物及びこれを用いた光記録媒体 |
| EP1834642A3 (en) * | 2006-03-08 | 2007-10-03 | National Institute of Immunology | 2-thioxothiazolidin-4-one compounds and compositions as antimicrobial and antimalarial agents targeting enoyl-ACP reductase of type II fatty acid synthesis pathway and other cell growth pathways |
| EP2117601A2 (en) * | 2006-12-22 | 2009-11-18 | The Regents of the University of California | Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| JP2011516499A (ja) * | 2008-04-04 | 2011-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 嚢胞性線維症膜コンダクタンス制御因子を阻害するための二価ヒドラジド化合物コンジュゲート |
-
2009
- 2009-03-25 EP EP09725813A patent/EP2279029A2/en active Pending
- 2009-03-25 MX MX2010010343A patent/MX2010010343A/es not_active Application Discontinuation
- 2009-03-25 BR BRPI0908706-0A patent/BRPI0908706A2/pt not_active IP Right Cessation
- 2009-03-25 AU AU2009228307A patent/AU2009228307A1/en not_active Abandoned
- 2009-03-25 CA CA2718436A patent/CA2718436A1/en not_active Abandoned
- 2009-03-25 US US12/934,621 patent/US20110105565A1/en not_active Abandoned
- 2009-03-25 JP JP2011502030A patent/JP2011517674A/ja active Pending
- 2009-03-25 KR KR1020107023735A patent/KR20100134063A/ko not_active Withdrawn
- 2009-03-25 WO PCT/US2009/038292 patent/WO2009120803A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011517674A (ja) | 2011-06-16 |
| WO2009120803A2 (en) | 2009-10-01 |
| EP2279029A2 (en) | 2011-02-02 |
| MX2010010343A (es) | 2010-10-15 |
| WO2009120803A3 (en) | 2009-12-30 |
| KR20100134063A (ko) | 2010-12-22 |
| AU2009228307A1 (en) | 2009-10-01 |
| CA2718436A1 (en) | 2009-10-01 |
| US20110105565A1 (en) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0908706A2 (pt) | Inibidores de mólecula pequena solúvel em água do regulador de condutância de transmembrana de fibrose cística | |
| BRPI0919930A2 (pt) | moduladores de regulador de condutância transmembrana de fibrose cística | |
| BRPI1012549A8 (pt) | moduladores do regulador da condutância da transmembrana de fibrose cística | |
| BRPI0910416A2 (pt) | conjugados de composto de hidrazia divalente para inibir regulador de condutância de transmembrana de fibrose cística | |
| BRPI0912243A2 (pt) | misturador de fluxos em linha | |
| HRP20170246T1 (hr) | Režim doziranja za selektivni agonist s1p1-receptora | |
| EP2285384A4 (en) | BORN SMALL MOLECULES | |
| BRPI0908066A2 (pt) | Dispensador de espuma | |
| BRPI0914841A2 (pt) | aparelho de massagem | |
| EP2348863A4 (en) | BORN SMALL MOLECULES | |
| BRPI0908491A2 (pt) | Inibidor de fibrose | |
| EP2303265A4 (en) | STABLE TOPICAL FORMULATION WITH VORICONAZOLE | |
| BRPI0914781A2 (pt) | Microbiocidas | |
| BRPI0916551A2 (pt) | dispositivo eletroquímico | |
| EP2359726A4 (en) | Shower device | |
| EP2351502A4 (en) | SCHAUMSTOFFDÜSE | |
| DK2324930T3 (da) | Vandsprøjteindretning | |
| BRPI0907963A2 (pt) | Derivados de indazola | |
| BRPI0914171A2 (pt) | dispositivo de revestimento | |
| EP2302092A4 (en) | BIAS sputtering | |
| DK2335032T3 (da) | In-line-måler | |
| DK2259869T3 (da) | Polymerskum | |
| BRPI0822525A2 (pt) | gerar mapas de sites | |
| EP2346268A4 (en) | ACOUSTIC DEVICE | |
| BRPI0911199A2 (pt) | microbiocidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |